{"id":1609,"date":"2004-12-01T12:00:00","date_gmt":"2004-12-01T11:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/mycophenolat-mofetil-versus-azathioprin-zur-praevention-akuter-abstossungsepisoden-nach-nierentransplantation"},"modified":"2004-12-01T12:00:00","modified_gmt":"2004-12-01T11:00:00","slug":"mycophenolat-mofetil-versus-azathioprin-zur-praevention-akuter-abstossungsepisoden-nach-nierentransplantation","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/mycophenolat-mofetil-versus-azathioprin-zur-praevention-akuter-abstossungsepisoden-nach-nierentransplantation","title":{"rendered":"Mycophenolat Mofetil versus Azathioprin zur Pr\u00e4vention akuter Absto\u00dfungsepisoden nach Nierentransplantation"},"content":{"rendered":"<p>Mycophenolat Mofetil (MMF) war Mitte der neunziger Jahre vor Einf\u00fchrung auf den internationalen Markt in drei gro\u00dfen Studien zur Pr\u00e4vention akuter Absto\u00dfungsepisoden nach Nierentransplantation gegen Azathioprin (1, 2) bzw. Plazebo (3) bei Patienten untersucht worden, die bereits Ciclosporin (CIC) erhielten. Die Ergebnisse dieser Studien wurden von Halloran et al. (4) noch einmal in einer gemeinsamen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mycophenolat Mofetil (MMF) war Mitte der neunziger Jahre vor Einf\u00fchrung auf den internationalen Markt in drei gro\u00dfen Studien zur Pr\u00e4vention akuter Absto\u00dfungsepisoden nach Nierentransplantation gegen Azathioprin (1, 2) bzw. Plazebo (3) bei Patienten untersucht worden, die bereits Ciclosporin (CIC) erhielten. Die Ergebnisse dieser Studien wurden von Halloran et al. (4) noch einmal in einer gemeinsamen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3445,1021],"class_list":["post-1609","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-mycophenolat-mofetil","tag-nierentransplantation"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1609"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1609\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1609"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1609"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}